A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

December 21, 2011

FDA Lacks Authority to Prevent Rising Number of Drug Shortages, Report Says

Pharmaceutical companies should be required to notify the U.S. Food and Drug Administration (FDA) of situations that may lead to drug shortages, thereby allowing the agency to address production issues and enhance product availability, according to a new report by the U.S. Government Accountability Office (GAO). 

Though an increasing drug shortage problem in the United States primarily involves injectable generic medications and rarely involves brand-name oral antiretrovirals, some of the treatments now unavailable because of production issues are needed by people living with HIV-associated health complications. 

According to its December 15 report, GAO says the number of drug shortages has grown substantially in recent years, a problem made worse by the fact that the FDA is constrained in its ability to protect the public health from the effects of these shortages. 

Nearly 1,2000 shortages were reported from January 2001, through June 2011, the report notes, many of which were injectable generic drugs for cancer and infectious diseases for which no suitable alternatives are available.  A record number of shortages—196 in total—were reported in 2010, the report authors point out, “and 2011 is on pace to surpass 2010’s record, with 146 shortages reported through June 20, 2011.”  

The drug shortages reviewed by GAO were generally caused by manufacturing problems and exacerbated by multiple difficulties. Twelve of the 15 drug shortages analyzed in detail were primarily caused by manufacturing problems, including those that resulted in manufacturing shutdowns, according to information provided by FDA and manufacturers.

One drug shortage example that has affected people living with HIV involves Doxil (doxorubicin), a chemotherapy used to treat Kaposi’s sarcoma (KS), produced by Ben Venue Laboratories, a subsidiary of Boehringer Ingelheim Pharmaceuticals. On November 19, the company announced that it was temporarily shutting down its Bedford, Ohio–based production plant after metal particles were detected in some of its drugs. More than a month later, plans to reopen the facility have not been announced and Doxil remains largely unavailable.

Though it is unclear if the FDA would have been able to prevent the shortage of Doxil—Ben Venue notes it is working with the agency to remedy the problem—the agency’s response to drug shortages is often limited by its lack of authority to require manufacturers to report potential or current shortages to agency officials. 

According to the GAO report, which analyzed FDA’s authority under the Food, Drug and Cosmetic Act and a review of relevant FDA regulations, policies, procedures and documents, the agency can prevent the majority of such shortages from occurring. However, it does not currently have the authority to require manufacturers to provide it with information about potential or current shortages, and therefore it can only prevent the shortages that it becomes aware of through voluntary reporting. 

FDA’s ability to protect the public health is also constrained by its own management challenges, the report suggests. The agency has not elevated the priority it places on its response to drug shortages—its Drug Shortage Program consists of only a small staff, for example—despite the rapid escalation of these shortages. “Not only have its resources not kept pace with this escalation,” the report states, “the agency has not developed the metrics to manage this growing public health problem.”

“The agency has not elevated the priority it places on its response to drug shortages, despite the rapid escalation of these shortages,” Marcia Crosse, director of the GAO health care office, told the U.S. Senate Committee on Health, Education, Labor and Pensions on December 15. “Although FDA recognizes the serious threat these shortages pose, we believe the agency can and must do more to protect the public health.”

In February 2011, Senator Amy Klobuchar (D–Minn.) and Senator Bob Casey (D–Penn.) introduced S. 296, the Preserving Access to Life Saving Medications Act, with a companion bill, HR 2245, introduced in the House in June by Representative Diana DeGette (D–Colo.) and 61 cosponsors. These pieces of legislation would require manufacturers to notify the FDA when they experience manufacturing problems or when a drug is to be discontinued. The bills would also provide the agency with improved capacity to prevent drug shortages.

Search: drug, shortages, FDA, Food and Drug Administration, Doxil, Klobuchar, Casey, Degette, Preserving Access to Life Saving Medications Act, S. 296, HR 2245


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (4 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter


Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.